St. John, Ashley L. http://orcid.org/0000-0001-5098-1044
Choi, Hae Woong http://orcid.org/0000-0001-9372-1875
Walker, Q. David
Blough, Bruce
Kuhn, Cynthia M.
Abraham, Soman N. http://orcid.org/0000-0002-1662-2096
Staats, Herman F. http://orcid.org/0000-0003-1039-1087
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (1R21DA029731-01, 1R21DA029731-01, 1R21DA029731-01)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
Article History
Received: 18 October 2019
Accepted: 14 January 2020
First Online: 5 February 2020
Competing interests
: H.F.S. and S.N.A. have been issued a US patent related to the use of synthetic peptides as vaccine adjuvants. (Peptide, adjuvants, vaccines, and methods of use. USPTO #9,301,999. Filed: September 28, 2010; Issued: April 5, 2016. H.F.S.; S.N.A., and Salvatore Pizzo.) The peptides described in our issued patent are novel analogs of the M7 peptide adjuvant used in the submitted manuscript. However, M7 peptide is not included in our issued patent and the patented peptide adjuvants are not utilized in this manuscript. Therefore, the authors declare that there are no competing interests.